Articles tagged with Myeloid Leukemia
Researchers developed a microfluidic device to alleviate limitations of conventional blood-filtering machines used in treating hyperleukocytosis in children. The new device separates blood cells by size without platelet loss or adverse effects, enabling safe leukapheresis procedures.
Researchers at MD Anderson have made significant breakthroughs in understanding pancreatic cancer's evolutionary process and developing new treatment strategies. They also discovered that surgical resection can enhance antitumor response in patients receiving immune checkpoint therapy for advanced kidney cancer.
Researchers at VCU Massey Comprehensive Cancer Center have identified an innovative combination treatment strategy that collaborates to kill AML cells. The new approach targets the SRC gene and MCL-1 protein, leading to increased cell death in leukemia cells. This discovery offers a promising new direction for leukemia treatment.
Key molecular applications in diagnosing and managing hematopoietic and lymphocytic neoplasms include comprehensive mutational profiling, aiding accurate diagnosis and prognostication. The use of targeted therapies against specific genetic abnormalities further refines treatment selection.
Researchers at MD Anderson Cancer Center have identified biomarkers for predicting treatment response in metastatic breast cancer and found a potential target for tumor progression in pancreatic cancer. Additionally, they discovered that abnormal chromosome changes predict survival in patients with secondary acute myeloid leukemia.
A new study has identified two cell types with distinct biological properties that respond differently to treatment after acquiring the same mutation. Understanding these differences is crucial for developing personalized therapies and preventing aggressive forms of cancer.
The Damon Runyon-St. Jude Pediatric Cancer Research Fellowship aims to address a funding gap for pediatric cancer research. The program supports innovative projects that could significantly impact the diagnosis or treatment of one or more pediatric cancers.
A new case report reveals a rare and aggressive form of leukemia developing from donor cells nine years after a stem cell transplant. The disease, driven by genetic mutations in key genes, progresses despite intensive treatment and ultimately proves fatal.
Researchers have identified a unique population of T cells that play a critical role in successful treatment of relapsed acute myeloid leukemia. A healthier immune environment in the bone marrow supports these cells and their cancer-fighting abilities.
Dana-Farber investigators pinpoint the importance of cell type and tumor microenvironment in determining DLI response. Patients who responded to DLI had distinct cellular populations in their bone marrow, which may indicate 'hot' or 'cold' forms of AML.
Researchers analyzed 101 Chinese AML samples and identified three subtypes with different molecular characteristics and clinical outcomes. The study also found potential drug combinations that could improve treatment efficacy for subtype S-II&III patients who benefited from allogenic haematopoietic stem cell transplantation.
The myeloMATCH program aims to improve precision medicine by matching patients with specific genetic signatures of their disease. Patients receive tailored treatment options based on the unique makeup of their cancer, offering hope for improved outcomes and increased survival rates.
Researchers have identified a promising new drug, lomonitinib, targeting treatment-resistant acute myeloid leukemia (AML) with FLT-3 mutation. Additionally, they developed a novel compound to target MALT1 protein in chronic lymphocytic leukemia (CLL), aiming to provide better control of the disease.
Researchers at Dana-Farber Cancer Institute have led three studies that provide new insights into treating acute myelogenous leukemia (AML) in various high-risk subtypes. The findings reveal that CPX-351 has a survival benefit for patients with AML-MR mutations, but may not be effective for those with TP53 or DDX41 mutations.
Researchers created a comprehensive map of blood cell changes from fetal development to old age, finding that leukemia cells can reflect young or old blood cell production. Patients with leukemia whose cells resemble young blood cells have a worse prognosis.
Researchers at MD Anderson Cancer Center presented findings on novel treatments for MDS, including luspatercept, which significantly reduced the need for blood transfusions in lower-risk patients. Additionally, a triplet therapy regimen improved survival in older adults with FLT3-mutated AML.
Researchers analyzed chromosomal chaos in leukemia cells and found that genetic and non-genetic factors drive functional heterogeneity. They identified therapeutic targets and alternatives for resistant subclones, providing a model for early identification of leukemia stem cells.
MD Anderson researchers have made significant advancements in treating chronic pain, myelodysplastic syndrome, and rare cancers. A novel treatment for chronic pain has been developed with reduced side effects, while targeted therapies like canakinumab show promise for personalized approaches.
More than 70 hematology researchers from the University of Miami Miller School of Medicine will showcase their work at the 66th ASH Annual Meeting & Exposition. Researchers from Sylvester Comprehensive Cancer Center are authors or co-authors on a significant number of posters presented during the event.
Marina Konopleva joins the Eradicating MRD in AML TeamLab to develop new ways to detect and target Minimal Residual Disease. MECCC has developed multiple targeted agents that have become standard of care for older AML patients, and will partner with Break Through Cancer to deepen understanding of MRD drivers.
The ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present several abstracts at the 66th American Society of Hematology Meeting & Exposition. Promising results from a phase 2 study in acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial show improved outcomes for patients with B-cell acute lymphobla...
Researchers found that blood cancer cells rewired their gene regulatory networks to evade drug treatment in Acute Myeloid Leukemia (AML), disrupting normal differentiation and growth. The study identified key findings, including changes in open chromatin regions and the loss of binding of RUNX1 and AP-1 transcription factors.
The myeloMATCH program offers a portfolio of biomarker-driven treatment trials to accelerate precision medicine in myeloid malignancies. Patients can enroll in clinical trials throughout their cancer treatment journey, with test results returned quickly to assign them to the most appropriate trial.
TP53 mutations are commonly associated with therapy-related AML and complex cytogenetics. Researchers found improved long-term outcomes when allo-HCT was performed during Complete Remission 1 (CR1), despite limited effective therapies for TP53-mutated AML.
A global study identified molecular predictors of survival among Black patients with acute myeloid leukemia (AML), suggesting a need to modify current AML risk layers. Ancestry-specific genetic factors and testing these in clinical trials are recommended.
Natural Killer (NK) cell-based therapies have shown promise in preclinical and clinical studies for treating Acute Myeloid Leukemia (AML), offering a potential cure with minimal prior antigen sensitization. However, the dysfunction of NK cells in AML patients poses a significant challenge that must be overcome to unlock their full ther...
The SWOG S1712 trial found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment significantly increased the percentage of patients with deep molecular responses, warranting treatment discontinuation. This combination may lead to improved health-related quality of life and reduced healthcare costs.
A Phase II trial found that a novel combination of decitabine, venetoclax, and ponatinib achieved complete remission in 80% of patients with advanced-phase chronic myeloid leukemia. The treatment showed promise even in patients with high-risk features and those who had received multiple prior therapies.
A four-year grant will help researchers find new clues to the interplay between Down syndrome and myeloid leukemia, focusing on enhancing antileukemic activity of chemotherapy drug cytarabine. The goal is to identify a novel treatment strategy to improve patient outcomes and prevent relapses in ML-DS patients.
Researchers have found a potential compound that pairs well with an IRAK4 inhibitor to kill AML cells by reducing c-Myc levels, a protein also driving cancer growth. The three-year LLS grant will allow further research into the effects of IRAK4 targeting on c-Myc.
Researchers suggest that hematopoietic stem and progenitor cells in the AML niche may retain an inflammatory memory, potentially leading to long-term functional consequences. This finding has significant implications for understanding the biology of acute myeloid leukemia (AML) and developing new cancer therapies.
Acute myeloid leukemia (AML) cells rely on structures called P-bodies to isolate mRNAs that encode proteins suppressing their growth. The discovery of this mechanism may lead to new anti-cancer therapies targeting P-body formation in AML.
Researchers highlight DDX41's distinct contribution to myeloid neoplasms with germline predisposition. The discovery sheds light on unique pathogenesis and disease phenotype associated with DDX41 variants.
A novel strategy using venetoclax and azacitidine demonstrates significant anti-cancer effect with mild toxicity for relapsed/refractory AML patients. The treatment showed markedly better survival rates after one year compared to a control group, with improved 'graft-versus-leukemia effects' via alterations of immune cells.
A new editorial paper discusses molecular and cytogenetic analyses used to identify distinct subtypes of acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS). Researchers found that around 15% of AML cases remain genetically unclassifiable, emphasizing the need for further research.
Researchers found that inhibiting the AGTR1 receptor with losartan disrupted cancer growth, slowed development and prolonged survival in mice. This targeted gene therapy also protected the heart against chemotherapy-induced cardiotoxicity.
Researchers at Purdue University have developed a patent-pending compound called HSN748 to treat drug-resistant acute myeloid leukemia (AML). The compound has been validated in tests with IU School of Medicine and demonstrated 100% survivability after 120 days. AML is a cancer that begins in bone marrow and can be difficult to treat du...
A study published in Blood Neoplasia reveals that older adults with acute myeloid leukemia can benefit from standard treatment, with roughly a quarter experiencing durable prolonged survival. The conventional treatment of venetoclax combined with a hypomethylating agent (HMA) is safe and effective for those over 80 years old.
A recent study published in Blood Neoplasia found that older adults with acute myeloid leukemia (AML) can derive benefit from the VEN-HMA regimen, which is the standard of care for older AML patients. The treatment was shown to durably prolong survival in approximately 20-25% of treated patients.
Dana-Farber researchers discovered a molecular complex called PI3Kgamma that supports the survival of certain leukemia cells. The team found that eganelisib, an existing medicine, can inhibit this complex and has shown promise in animal models and clinical trials.
A new study published in JAMA Oncology highlights the importance of testing for measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) undergoing bone marrow transplants. The researchers found that detecting MRD can help predict cancer recurrence and improve patient outcomes.
Researchers highlight the role of post-transcriptional RNA modifications in AML pathogenesis, identifying m6A and m7G regulators as potential therapeutic targets. Targeted therapies, including selective inhibitors and Traditional Chinese Medicine compounds, show promise in promoting cell differentiation and reversing AML phenotypes.
Researchers discovered MIA-602's effectiveness against Doxorubicin-resistant acute myeloid leukemia (AML), demonstrating reduced cell viability and tumor volume. The study suggests MIA-602 as a potential alternative treatment approach for AML, potentially circumventing chemotherapy side effects.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
Researchers identify mitochondrial priming as a key driver of multi-drug resistance in relapsed acute myeloid leukemia. A new technique called dynamic BH3 profiling reveals anti-cancer drugs capable of overcoming resistance.
A novel gene-based prognostic tool has been developed to personalize treatment in pediatric acute myeloid leukemia (AML). The five-gene transcriptional signature improves prognostic accuracy and identifies high-risk patients. It also streamlines the panel of genetic markers without compromising predictive efficacy.
Researchers discovered genes encoding growth regulators normally not present in myeloid cells are expressed by leukaemic stem cells, allowing them to grow. Repurposed drugs targeting these receptors show promise in blocking stem cell growth and preventing disease relapse in specific types of AML.
Researchers discovered a link between single cancer cell mutations and clinical response to epigenetic therapy in myelodysplastic syndrome. Patients showing treatment benefits had decreased mutation counts in stem cells and immature granulocytes, suggesting early tumor elimination is key to therapy success.
A new proteogenomics study provides insights into how drug resistance develops in acute myeloid leukemia, offering a potential path forward for treatment. Researchers identified specific proteins and molecular locations that play a key role in determining protein activity, which could help doctors switch to alternative medications.
Researchers at the John Theurer Cancer Center have co-authored a study on oral decitabine-cedazuridine therapy, which is now shown to be pharmacologically and pharmacodynamically equivalent to its intravenous counterpart. This innovation has significant potential for patient benefit and improved comfort in cancer treatment.
A research team at HKUMed has identified PLK4 as a novel therapeutic target for acute myeloid leukaemia (AML) carrying the TP53 mutation. The study found that PLK4 inhibition induces DNA damage, cell ageing and abnormal cell division, triggering the immune system via the cGAS-STING pathway.
Researchers discuss reductive carboxylation of glutamine as a potential target in acute myeloid leukemia (AML), an aggressive cancer with poor patient outcomes. The approach aims to weaken tumor cell survival mechanisms, potentially leading to novel therapies and improved patient outcomes.
The study classifies pediatric acute myeloid leukemia (pAML) into 23 distinct molecular categories, revealing unique biological characteristics and drivers of the disease. This classification provides a path forward for clinicians to identify distinct pAML sub-types and guide treatment decisions.
Researchers at Tokyo Medical and Dental University characterize myeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) using multiomics approaches, revealing distinct molecular features. This work provides crucial details for accurate diagnoses and therapeutic decisions.
A new AI-based method developed by IT specialists and physicians at the University of Münster can predict genetic features in leukaemia patients using high-resolution bone marrow images. The method extracts genetic aberrations from large datasets, enabling early diagnosis and targeted treatment without waiting for genetic analyses.
A new study found that removing the RUNX1 transcription factor and its target gene can lead to a network collapse, causing cancer cell death in a type of aggressive leukemia. This breakthrough identifies specific protein targets for potential treatments.
A microbial sensor, Nod1, plays a crucial role in the development of blood stem cells. The discovery could lead to the creation of patient-derived blood stem cells, eliminating the need for bone marrow transplants and improving lives of leukemia, lymphoma, and anemia patients. Researchers are continuing to study the complex interaction...
A new study led by Dr. Mikkael Sekeres found that patients with a common form of acute myeloid leukemia reported better quality of life when treated with quizartinib, which targets the FLT3-ITD mutation. The study also showed minimal side effects and improved survival rates compared to those who didn't receive the drug.
A new therapy, venetoclax, has improved survival rates for Non-Hispanic Black patients with acute myeloid leukemia, narrowing the racial disparity. The study analyzed over 3,000 adult patients diagnosed between 2014 and 2022 and found a significant increase in two-year overall survival rates.
Researchers at University of Cincinnati Cancer Center present Phase 2 clinical trial results for a new BTK inhibitor treatment that offers potential for improved efficacy and safety in chronic lymphocytic leukemia. The study also explores the use of IRAK4 inhibitors to target acute myeloid leukemia cells, with promising results.